From: MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Subgroup | No. comparisons | TG vs. TT | GG vs. TT | GG vs. TT/TG | GG/TG vs. TT | ||||
---|---|---|---|---|---|---|---|---|---|
 |  | OR (95% CI) | I-squre (%) | OR (95% CI) | I-squre (%) | OR (95% CI) | I-squre (%) | OR (95% CI) | I-squre (%) |
Total | 78 | 1.10* (1.03-1.17) | 51.7 | 1.25* (1.13-1.37) | 66.9 | 1.18* (1.10-1.27) | 55.1 | 1.14* (1.07-1.22) | 62.2 |
Tumor site | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Breast | 18 | 1.09* (1.00-1.19) | 12.8 | 1.09 (0.96-1.24) | 20.7 | 1.05 (0.94-1.17) | 19.5 | 1.09* (1.01-1.17) | 9.1 |
   Lung | 10 | 1.06 (0.93-1.22) | 64.8 | 1.21 (0.99-1.47) | 67.8 | 1.12 (0.99-1.27) | 42.7 | 1.10 (0.95-1.27) | 72.4 |
   Ovarian | 3 | 0.85 (0.63-1.16) | 25.2 | 0.79 (0.48-1.28) | 52.3 | 0.89 (0.63-1.25) | 33.1 | 0.82 (0.57-1.18) | 50.5 |
   Pancreatic | 2 | 1.55 (0.98-2.46) | 59 | 1.56 (0.66-3.68) | 74.6 | 1.24 (0.68-2.24) | 56.4 | 1.54 (0.90-2.65) | 73 |
   Blood | 4 | 1.08 (0.65-1.79) | 79.4 | 1.11 (0.57-2.17) | 80.3 | 1.09 (0.71-1.68) | 63.8 | 1.10 (0.67-1.82) | 81.6 |
   Brain | 5 | 1.47* (1.06-2.03) | 57.6 | 1.18* (1.08-3.03) | 69.5 | 1.38 (0.94-2.01) | 55.9 | 1.51* (1.10-2.07) | 61.3 |
   Colorectal | 6 | 1.14 (0.89-1.47) | 51.2 | 1.05 (0.65-1.68) | 74.4 | 1.00 (0.67-1.49) | 70 | 1.13 (0.85-1.50) | 65.5 |
   Esophageal | 2 | 1.11 (0.86-1.43) | 36 | 1.26 (0.92-1.72) | 51.2 | 1.28 (0.97-1.69) | 63.1 | 1.18 (1.00-1.41) | 0 |
   Head-neck | 4 | 0.92 (0.67-1.28) | 71.6 | 1.01 (0.69-1.47) | 72.3 | 1.11 (0.96-1.29) | 1.7 | 0.94 (0.67-1.34) | 77.8 |
   Liver | 4 | 1.57* (1.18-2.09) | 0 | 2.24*(1.57-3.18) | 0 | 1.65* (1.25-2.17) | 0 | 1.76* (1.34-2.31) | 0 |
   Skin | 4 | 1.00 (0.86-1.16) | 0.4 | 1.05 (0.85-1.29) | 1.2 | 1.05 (0.86-1.27) | 0 | 1.01 (0.86-1.19) | 26.6 |
   Stomach | 5 | 1.03 (0.75-1.42) | 72.2 | 1.54* (1.04-2.29) | 76.4 | 1.49* (1.20-1.84) | 53.2 | 1.18 (0.84-1.65) | 77.6 |
   Uterus | 8 | 0.95 (0.81-1.11) | 0 | 1.34* (1.07-1.69) | 5.3 | 1.26 (0.92-1.72) | 51.2 | 0.81* (0.70-0.94) | 0 |
   Other | 3 | 0.98 (0.72-1.32) | 14.6 | 1.14 (0.63-2.08) | 66.8 | 1.16 (0.72-1.85) | 62.6 | 1.02 (0.67-1.52) | 55 |
Racial descent | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   African | 3 | 1.22 (0.80-1.86) | 61.2 | 0.75 (0.40-1.41) | 0 | 0.73 (0.39-1.36) | 0 | 1.16 (0.80-1.70) | 56 |
   European | 34 | 1.05 (0.98-1.13) | 34.8 | 1.13* (1.01-1.25) | 40.8 | 1.10* (1.00-1.20) | 30.8 | 1.08* (1.00-1.16) | 42.1 |
   Asian | 32 | 1.11 (0.99-1.24) | 58.4 | 1.36* (1.18-1.56) | 68.6 | 1.27* (1.15-1.40) | 58.6 | 1.18* (1.05-1.32) | 65.8 |
   Mixed | 9 | 1.10 (0.91-1.32) | 49.7 | 1.16 (0.86-1.56) | 59.6 | 1.08 (0.88-1.35) | 37.3 | 1.10 (0.92-1.32) | 52.7 |
p53 mutation status | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Positive | 7 | 1.09 (0.89-1.34) | 0 | 1.17 (0.75-1.82) | 59.4 | 1.09 (0.70-1.69) | 70.3 | 1.12 (0.92-1.36) | 0 |
   Negative | 7 | 1.06 (0.85-1.30) | 4.1 | 0.95 (0.72-1.25) | 0 | 0.97 (0.76-1.22) | 0 | 1.03 (0.85-1.25) | 0 |